185
Participants
Start Date
November 30, 2011
Primary Completion Date
May 30, 2014
Study Completion Date
April 21, 2017
Elotuzumab
Solution; Intravenous (IV); 10 mg/kg; (Cycles 1 \& 2: Days 1, 8 \& 15; Cycles 3-8: Days 1 \& 11; Cycle 9+: Days 1 \& 15); Until subject meets criteria for discontinuation of study drug
Bortezomib
Solution; IV; 1.3 mg/m2; (Cycles 1 - 8: Days 1, 4, 8, 11; Cycles 9+: Days 1, 8, 15); Until subject meets criteria for discontinuation of study drug
Dexamethasone
Tablets; Oral; 20 mg; (Cycles 1\& 2: once daily on Days 2, 4, 5, 8, 9, 11; Cycles 3-8: once daily on Days 2, 4, 5, 9, 12; Cycles 9+: once daily on Days 2, 8, 9, 16); Until subject meets criteria for discontinuation of study drug
Dexamethasone
Tablets; Oral; 8 mg; (Cycles 1\& 2: Days 1, 8, 15; Cycles 3-8: Days 1 \&11; Cycles 9+; Days 1 \& 15); Until subject meets criteria for discontinuation of study drug
Dexamethasone
Solution; IV; 8 mg; (Cycles 1\& 2: Days 1, 8, 15; Cycles 3-8: Days 1 \&11; Cycles 9+; Days 1 \& 15); Until subject meets criteria for discontinuation of study drug
Dexamethasone
Tablets; Oral; 20 mg; (Cycles 1-8 once daily on Days 1, 2, 4, 5, 8, 9, 11, 12; Cycles 9+ once daily on Days 1, 2, 8, 9, 15, 16); Until subject meets criteria for discontinuation of study drug
Local Institution, Roma
Local Institution, Torino
The Western Pennsylvania Hospital, Pittsburgh
Local Institution, Santiago Compostela
Local Institution, Genova
Penn State Hershey Cancer Institute, Hershey
Penn State Hershey Cancer Inst, Hershey
Cancer Care Associates, Bethlehem
Local Institution, Milan
Local Institution, Baltimore
St. Agnes Hospital, Baltimore
Local Institution, Fairfax
Local Institution, Brescia
Waverly Hematology Oncology, Cary
Local Institution, Madrid
Medical University Of South Carolina, Charleston
Local Institution, Greenville
Local Institution, Murcia
Local Institution, Toulouse
Cancer Specialists of North FL, Jacksonville
Mount Sinai Comprehensive Cancer Center, Miami Beach
Palm Beach Cancer Institute, West Palm Beach
Local Institution, Salamanca
Local Institution, Grenoble
Local Institution, Bologna
University Of Kentucky Markey Cancer Center, Lexington
Local Institution, Modena
Pikeville Medical Center Leonard Lawson Cancer Center, Pikeville
Local Institution, Hazard
Local Institution, Nantes
Local Institution, Toledo
Local Institution, Valencia
Local Institution, Valencia
Investigative Clinical Research Of Indiana, Llc, Indianapolis
Local Institution, Meldola (fc)
Local Institution, Rimini
Local Institution, Ravenna
Henry Ford Health System, Detroit
Local Institution, Zaragoza
Local Institution, Florence
Local Institution, Vandœuvre-lès-Nancy
Local Institution, Lille
Oncology Specialists, S.C., Park Ridge
Local Institution, Ancona
University Of Chicago Medical Center, Chicago
Local Institution, Urbana
Local Institution, Decatur
Washington University School Of Medicine, St Louis
Local Institution, Pescara
Mercy Medical Research Institute, Springfield
Local Institution, Bari
Cancer Center Of Acadiana, Lafayette
Local Institution, Shreveport
Local Institution, Le Mans
Local Institution, Lecce
Local Institution, Paris
Charles A. Sammons Cancer Center, Dallas
Northwest Cancer Center, Houston
Southern Nevada Cancer Research Foundation, Las Vegas
USC Norris Comprehensive Cancer Center, Los Angeles
Ucla Department Of Medicine, Los Angeles
Local Institution, Long Beach
Sharp Clinical Oncology Research, San Diego
Medical Oncology Care Associates, Orange
Compassionate Cancer Res Grp, Corona
Local Institution, Corona
Kaiser Permanente Medical Center, Vallejo
Local Institution, Vallejo
Kaiser Permanente-Moanalua Medical Center, Honolulu
Local Institution, Seattle
Dana-Farber Cancer Institute, Boston
Local Institution, Worcester
Local Institution, Halifax
Local Institution, Roma
Local Institution, Rome
Local Institution, Roma
Local Institution, Barcelona
Lead Sponsor
Collaborators (1)
AbbVie
INDUSTRY
Bristol-Myers Squibb
INDUSTRY